Master Protocols for Drug and Biological Product Development; Guidance for Industry; Draft Guidance
Details
The document's own metadata, straight from the source system.
- Title
- Master Protocols for Drug and Biological Product Development; Guidance for Industry; Draft Guidance
- Posted
- Dec 22, 2023
- Comment period
- Dec 22, 2023 – Mar 22, 2024
- Topics
Overview
What the public is saying — stance, who's commenting, and the issues they raise.
Stance breakdown
Who commented
Breakdown by commenter type.
Comments over time
Weekly arrivals, stacked by stance.
Support × commenter type
How each type splits across stance.
Issues raised
The docket's canonical issues. Select one to browse its comments.
Position map
Who stands where on each issue?
Every non-silent position is backed by an excerpt from the comment.
Issues shown
Choose up to five.
| Organization | Master protocol design | Master protocols guidance |
|---|
2 organization-typed comments could not be identified.
Explorer
Every mirrored comment — filter by stance, campaign, or issue.
- Jun 23, 2026Comment from Yojana PatilSupportOther
The commenter provides technical feedback on the draft guidance for Master Protocols for Drug and Biological Product Development. They suggest specific improvements regarding Diversity Action Plans, endpoint harmonization in basket trials, operational mechanics for database locks, and biomarker/diagnostic assay validation.
Read comment → - Mar 21, 2024Comment from Daiichi SankyoSupportBusiness📎 Attachment
Daiichi Sankyo, a global pharmaceutical company, submitted comments providing specific technical feedback and requests for clarification on the draft guidance for master protocols. They advocate for more detailed guidance on oncology trials, randomization practicalities, and the inclusion of combination regimens.
Read comment → - Mar 21, 2024Comment from AstrazenecaSupportBusiness📎 Attachment
AstraZeneca supports the draft guidance on Master Protocols for Drug and Biological Product Development, noting it is timely and supportive of innovation. The company suggests expanding the guidance to include more detail on basket trials, precision medicine, rare diseases, and practical considerations like patient centricity and sample size estimation.
Read comment → - Dec 25, 2023Comment from Cong ChenOtherIndividual
The commenter provides technical feedback regarding the statistical allocation ratios for umbrella trials in drug development. They argue that the current recommendations may not be optimal for trials where experimental arms enter at different times or have overlapping populations, citing specific research for a more complex formula.
Read comment →